Norethindrone Acetate Tablets, USP

Manufacturer
Golden State Medical Supply, Inc.
Effective date
2025-01-14
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 21:22:53

Label at a glance#

ProductNorethindrone Acetate
Active ingredientNORETHINDRONE ACETATE
Label structure11 sections

Indications and uses

Norethindrone Acetate Tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone Acetate Tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Dosage and administration

Therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient. 2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven ...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Norethindrone Acetate Tablets, USP (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. The structural formula is as follows:

Norethindrone Acetate structural formula
Norethindrone Acetate structural formula

C 22H 28O 3M.W. 340.46

Each Norethindrone Acetate Tablet, USP for oral administration, contains norethindrone acetate, USP 5 mg. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone.

Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

SPL UNCLASSIFIED SECTION

Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from norethindrone acetate tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of norethindrone acetate in 29 healthy female volunteers are summarized in Table 1.

Table 1

Pharmacokinetic Parameters after a Single Dose of
Norethindrone Acetate in Healthy Women

Norethindrone Acetate (n = 29) Arithmetic Mean ± SD

Norethindrone (NET)

AUC (0-inf)(ng/ml*h)

166.90 ± 56.28

C max(ng/ml)

26.19 ± 6.19

t max(h)

1.83 ± 0.58

t 1/2(h)

8.51 ± 2.19

AUC = area under the curve,
C max= maximum plasma concentration,
t max= time at maximum plasma concentration,
t 1/2= half-life,
SD = standard deviation

Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions

Figure 1
Figure 1
Effect of Food

SPL UNCLASSIFIED SECTION

The effect of food administration on the pharmacokinetics of norethindrone acetate has not been studied.

Distribution

SPL UNCLASSIFIED SECTION

Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg.

Metabolism

SPL UNCLASSIFIED SECTION

Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.

Excretion

SPL UNCLASSIFIED SECTION

Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of norethindrone acetate is approximately 9 hours.

Special Populations

SPL UNCLASSIFIED SECTION

Geriatrics

SPL UNCLASSIFIED SECTION

The effect of age on the pharmacokinetics of norethindrone after norethindrone acetate administration has not been evaluated.

Race

SPL UNCLASSIFIED SECTION

The effect of race on the disposition of norethindrone after norethindrone acetate administration has not been evaluated.

Renal Insufficiency

SPL UNCLASSIFIED SECTION

The effect of renal disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function.

Hepatic Insufficiency

SPL UNCLASSIFIED SECTION

The effect of hepatic disease on the disposition of norethindrone after norethindrone acetate administration has not been evaluated. However, norethindrone acetate is contraindicated in markedly impaired liver function or liver disease.

Drug Interactions

SPL UNCLASSIFIED SECTION

No pharmacokinetic drug interaction studies investigating any drug-drug interactions with norethindrone acetate have been conducted.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Norethindrone Acetate Tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone Acetate Tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

  • Known or suspected pregnancy. There is no indication for norethindrone acetate in pregnancy. (See PRECAUTIONS.)
  • Undiagnosed vaginal bleeding
  • Known, suspected or history of cancer of the breast
  • Active deep vein thrombosis, pulmonary embolism or history of these conditions
  • Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)
  • Impaired liver function or liver disease
  • As a diagnostic test for pregnancy
  • Hypersensitivity to any of the drug components

WARNINGS

WARNINGS SECTION

  1. Cardiovascular Disorders
    Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
  2. Visual Abnormalities
    Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

  • Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation.
  • In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated.
  • Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
  • Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy.
  • The pathologist should be advised of progestin therapy when relevant specimens are submitted.

Information for the Patient

INFORMATION FOR PATIENTS SECTION

Healthcare providers are advised to discuss the PATIENT INFORMATIONleaflet with patients for whom they prescribe norethindrone acetate tablets.

Drug/Laboratory Tests Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

The following laboratory test results may be altered by the use of estrogen/progestin combination drugs:

  1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor X aand antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
  2. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T 4levels (by column or by radioimmunoassay) or T 3levels by radioimmunoassay. T 3resin uptake is decreased, reflecting the elevated TBG. Free T 4and free T 3concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
  3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
  4. Increased plasma HDL and HDL 2cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels.
  5. Impaired glucose metabolism.
  6. Reduced response to metyrapone test.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established.

Pregnancy

PREGNANCY SECTION

Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses.

Nursing Mothers

NURSING MOTHERS SECTION

Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Norethindrone acetate tablets are not indicated in children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

See  WARNINGSand PRECAUTIONS.

The following adverse reactions have been observed in women taking progestins:

  • Breakthrough bleeding
  • Spotting
  • Change in menstrual flow
  • Amenorrhea
  • Edema
  • Changes in weight (decreases, increases)
  • Changes in the cervical squamo-columnar junction and cervical secretions
  • Cholestatic jaundice
  • Rash (allergic) with and without pruritus
  • Melasma or chloasma
  • Clinical depression
  • Acne
  • Breast enlargement/tenderness
  • Headache/migraine
  • Urticaria
  • Abnormalities of liver tests (i.e., AST, ALT, Bilirubin)
  • Decreased HDL cholesterol and increased LDL/HDL ratio
  • Mood swings
  • Nausea
  • Insomnia
  • Anaphylactic/anaphylactoid reactions
  • Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism)
  • Optic neuritis (which may lead to partial or complete loss of vision)

To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Therapy with norethindrone acetate tablets must be adapted to the specific indications and therapeutic response of the individual patient.

Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology

SPL UNCLASSIFIED SECTION

2.5 to 10 mg norethindrone acetate tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen.

Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing norethindrone acetate tablets therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with norethindrone acetate tablets.

Endometriosis

SPL UNCLASSIFIED SECTION

Initial daily dosage of 5 mg norethindrone acetate tablets for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of norethindrone acetate tablets is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination.

HOW SUPPLIED

HOW SUPPLIED SECTION

Norethindrone Acetate Tablets, USP are available as:

5 mg:

White, oval, flat-faced, beveled-edge, scored tablet. Debossed with stylized b on one side and 211/5 on the scored side. Available in bottles of 50 tablets (NDC 51407-599-50).

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

Keep this and all medications out of the reach of children.

Manufactured For:
Teva Pharmaceuticals
Parsippany, NJ 07054

Rev. B 11/2022

Marketed by:

GSMS, Inc.

Camarillo, CA 93012 USA

PATIENT INFORMATION

SPL PATIENT PACKAGE INSERT SECTION

Norethindrone Acetate (nor eth′ in drone as′ e tate) Tablets, USP

Read this PATIENT INFORMATIONbefore you start taking norethindrone acetate tablets and read what you get each time you refill norethindrone acetate tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition.

What is the most important information I should know about norethindrone acetate (A Progestin Hormone) tablets?

  • Do not use norethindrone acetate tablets if you are pregnant, breastfeeding or are trying to conceive.
  • Do not use norethindrone acetate tablets if you have had a previous blood clot, stroke, or heart attack.
  • Do not use norethindrone acetate tablets if you are postmenopausal.

What are norethindrone acetate tablets?

Norethindrone acetate tablets are similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide norethindrone acetate tablets as individual tablets.

What are norethindrone acetate tablets used for?

Norethindrone acetate tablets are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance.

Who should not take norethindrone acetate tablets?

You should not take norethindrone acetate tablets if you are postmenopausal, pregnant, or breastfeeding.

You should not take norethindrone acetate tablets if you have the following conditions:

  • Known or suspected pregnancy. Norethindrone acetate tablets are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take norethindrone acetate tablets during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take norethindrone acetate tablets and later find out you were pregnant, talk with your healthcare provider right away.
  • History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions
  • Liver impairment or disease
  • Known or suspected cancer of the breast.If you have or had cancer of the breast, talk with your healthcare provider about whether you should take norethindrone acetate tablets.
  • Undiagnosed vaginal bleeding
  • Hypersensitivity to norethindrone acetate tablets. See the end of this leaflet for a list of all of the ingredients in norethindrone acetate tablets.

What are the risks associated with norethindrone acetate tablets?

  • Risk to the Fetus

Norethindrone acetate tablets should not be used if you are pregnant. Norethindrone acetate tablets are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy.

You should avoid using norethindrone acetate tablets during pregnancy. If you take Norethindrone acetate tablets and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible.

  • Abnormal Blood Clotting

Use of progestational drugs, such as norethindrone acetate tablets, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug.

  • Eye Abnormalities

Discontinue norethindrone acetate tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine.

These are some of the warning signs of serious side effects with progestin therapy

  • Breast lumps
  • Dizziness and faintness
  • Changes in speech
  • Severe headaches
  • Chest pain
  • Shortness of breath
  • Pains in your legs
  • Changes in vision

Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.

Common side effects include

  • Headache
  • Breast pain
  • Irregular vaginal bleeding or spotting
  • Stomach/abdominal cramps/bloating
  • Nausea and vomiting
  • Hair loss

Other side effects include

  • High blood pressure
  • Liver problems
  • High blood sugar
  • Fluid retention
  • Enlargements of benign tumors of the uterus (“fibroids”)
  • Vaginal yeast infections
  • Mental depression

These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist.

What can I do to lower my chances of getting a serious side effect with norethindrone acetate tablets?

  • Talk with your healthcare provider regularly about whether you should continue taking norethindrone acetate tablets.
  • Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
  • If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks.

General information about the safe and effective use of norethindrone acetate tablets

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take norethindrone acetate tablets for conditions for which it was not prescribed. Do not give norethindrone acetate tablets to other people, even if they have the same symptoms you have. It may harm them.

Keep norethindrone acetate tablets out of the reach of children.

This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about norethindrone acetate tablets that is written for health professionals.

What are the ingredients in norethindrone acetate tablets?

Norethindrone acetate tablets contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.

Manufactured For:
Teva Pharmaceuticals
Parsippany, NJ 07054

Rev. B 11/2022

Marketed by:

GSMS, Inc.

Camarillo, CA 93012 USA

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51407-599-50

Norethindrone
Acetate
Tablets, USP
5 mg

ORALLY ACTIVE PROGESTIN

PHARMACIST: Dispense the
accompanying Patient Information
Leaflet to each patient.

Rx only
50 TABLETS

51407-599-50OL - Norethindrone Acetate 5 mg - Rev. 0125.jpg51407-599-50OL - Norethindrone Acetate 5 mg - Rev. 0125.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1000405norethindrone acetate 5 MG Oral TabletPSN1
1000405norethindrone acetate 5 MG Oral TabletSCD1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NORETHINDRONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d39a542a-f5b0-4c2d-a820-0f5d39e6621fProduct name120250307
859c4b0b-8cba-4f41-9afe-cc181a01fb62Product name220240215
0d9f32e2-f85b-4d63-9f04-b06059c34749Product name320230323
833edb59-a012-45c2-aff5-2ed74b66fa59Product name120201207
cec4644c-0fed-4608-a5ea-d3a1b1b6d697Product name220200728
00a01e22-7ea3-6f8f-0cc1-380aac10f424Product name620200716
f4d31098-441e-52d3-27f1-49c829f8a3a1Product name520190703
c21bcd2e-ecbd-48e6-ab68-12cc12256c0fProduct name220190213
c6636356-4ccb-40e9-a952-59eb1f2fc859Product name420180806
e042bc86-5d40-8945-82f8-de9dd95420ddProduct name620180606
390e6d23-3a11-4327-9294-c958a378baaeProduct name420180124
b651f154-0364-4007-9dc6-9d33036db1d7Product name420170808
3395ac9b-f30b-4991-80ba-fd5196be0214Product name320170802
a5e2d962-d98c-4fbf-8183-ffd42dd01e19Product name620170711
00606b81-6e33-4c38-9ca9-bd14bd74d84cProduct name420170501
f4ce24e8-8632-4fad-9984-b693f985f80fProduct name320170501
b17c5419-b38b-579f-10bc-8a4ce69fc044Product name520170316
f6ac5560-6d3b-d281-41d2-adc50d283c20Product name320170228
01996782-abcb-4e6d-bcaf-4a23e6a95c0cProduct name120160714
2aecf0b6-88a0-49e5-92e1-983c700c116cProduct name120151222
61972742-5d4d-491d-a881-b6bc3a011577Product name120151113
23ede539-308f-46e5-817b-41ef23af8d40Product name120150930
425e3610-bbe8-4d70-9c46-8cf09afc4e4dProduct name120150930
5e13e814-349e-3480-99f3-ee22a591426fProduct name220150518
63e5a7e1-a373-7c98-ef5d-a8a5e0a755b3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
51407-599-50Norethindrone Acetate50 in 1 BOTTLETABLET501

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
51407-599NORETHINDRONE ACETATE TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]1Current NDC, 1 package rows20250116_2bb29135-6e9b-a9e2-e063-6394a90ae9e4.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51407-599-50EA - Each51407-599f397b6f2-1f92-4049-b94d-aef81c29a9fe12025-02-10
0555-0211-10EA - Each0555-021128513b26-4306-439a-90d6-ff69a41b827312013-02-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51407-59951407-599-50
0555-0211

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075951-001NORETHINDRONE ACETATENORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075951-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2584e616aacf4f…
2026-08-18 06:07:402026-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-252680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-251e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-258072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-254b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2587673890dc5c…
2021-03-12 10:30 UTC2021-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-258869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253f01610625f2…
2019-09-15 20:21 UTC2019-09A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25b00525d2431f…
2019-07-19 19:46 UTC2019-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-256a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-251c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-259b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253f0d92c62455…
2023-05-13 08:27 UTC2023-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25053a50430f4f…
2023-01-26 05:58 UTC2023-01A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A075951-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A075951-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075951-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075951-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075951-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075951-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075951-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075951-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075951-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075951-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075951-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075951-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075951-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075951-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075951-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075951-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075951-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075951-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075951-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075951-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075951-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075951-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075951-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A075951-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075951-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075951-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075951-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A075951-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A075951-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075951-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075951-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075951-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075951-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075951-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075951-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075951-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075951-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A075951-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075951-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075951-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Norethindrone AcetateNORETHINDRONE ACETATEGolden State Medical Supply, Inc.2bb29135-6e9b-a9e2-e063-6394a90ae9e42025-01-14Warnings, Adverse reactionsExact identifier
ndc (package): 51407-599-50
ndc (product): 51407-599
ndc11 (package): 51407059950
spl id: 2bb2a27e-11f5-a9fb-e063-6394a90a1ea8
spl set id: 2bb29135-6e9b-a9e2-e063-6394a90ae9e4
Norethindrone AcetateNORETHINDRONE ACETATETeva Pharmaceuticals USA, Inc.f73f9807-4af6-4faa-ba9a-656a47a4c5e02022-11-30Warnings, Adverse reactionsExact identifier
ndc (product): 0555-0211

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.